These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 32324951)

  • 1. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics.
    Ghosh AK; Brindisi M; Shahabi D; Chapman ME; Mesecar AD
    ChemMedChem; 2020 Jun; 15(11):907-932. PubMed ID: 32324951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.
    Al-Horani RA; Kar S
    Viruses; 2020 Sep; 12(10):. PubMed ID: 32993173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.
    Pokhrel R; Chapagain P; Siltberg-Liberles J
    J Med Microbiol; 2020 Jun; 69(6):864-873. PubMed ID: 32469301
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
    Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S
    Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Drug Discovery Using Intensive Approaches.
    Asai A; Konno M; Ozaki M; Otsuka C; Vecchione A; Arai T; Kitagawa T; Ofusa K; Yabumoto M; Hirotsu T; Taniguchi M; Eguchi H; Doki Y; Ishii H
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives for repurposing drugs for the coronavirus disease 2019.
    Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
    Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
    Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
    Pillaiyar T; Wendt LL; Manickam M; Easwaran M
    Med Res Rev; 2021 Jan; 41(1):72-135. PubMed ID: 32852058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.
    Yadav M; Dhagat S; Eswari JS
    Eur J Pharm Sci; 2020 Dec; 155():105522. PubMed ID: 32827661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
    Huang F; Li Y; Leung EL; Liu X; Liu K; Wang Q; Lan Y; Li X; Yu H; Cui L; Luo H; Luo L
    Pharmacol Res; 2020 Aug; 158():104929. PubMed ID: 32442720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.